Dasatinib carbaldehyde

Target: This ligand targets BCR-ABL/ABL1 and Src-family tyrosine kinases in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for BCR-ABL/ABL1 and Src-family tyrosine kinases. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings BCR-ABL/ABL1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC E3 Ligand Recruitment: Dasatinib carbaldehyde can serve as a kinase-binding warhead in PROTACs to recruit an E3 ligase via a designed linker. By exploiting Dasatinib’s affinity for target kinases, such constructs can promote ubiquitination and proteasomal degradation, enabling systematic evaluation of degradation potency and selectivity across kinase families.

• Kinase Degradation Mapping Studies: As a reactive aldehyde derivative, Dasatinib carbaldehyde is well-suited for conjugation strategies that generate PROTAC libraries targeting specific kinases. Researchers can use these tools to map which kinase isoforms are efficiently degraded, quantify knockdown versus degradation effects, and determine how linker length and attachment geometry influence ternary complex formation.

• Ternary Complex Optimization: Incorporating Dasatinib carbaldehyde into PROTAC designs supports studies of ternary complex stability between the kinase, the E3 ligase, and the chimera. Experimental optimization can assess whether improved binding kinetics and spatial orientation enhance ubiquitin transfer, thereby increasing degradation efficiency relative to simple kinase inhibition.

• Mechanism of Degradation Profiling: PROTACs derived from Dasatinib carbaldehyde can be used to dissect degradation mechanisms, including dependence on the ubiquitin-proteasome pathway and E3 ligase engagement. By combining degradation readouts with ubiquitination assays and proteasome inhibition controls, researchers can distinguish degron-driven removal from off-target signaling suppression.

Dasatinib carbaldehyde is a ABL/Src-family kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Dasatinib carbaldehyde is characterized by aldehyde/oxime-compatible carbonyl functionality. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The aldehyde or oxime-related handle is compatible with oxime, hydrazone, reductive amination, or secondary functionalization strategies for linker introduction. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.